Neel Shah, MD
Vascular Neurology · Midland, TXNPI 1861752529
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,798, 4.8 times the $377 reported in 2019.
Across 157 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$350
- Novartis$349
- UCB, Inc.$291
- SK Life Science, Inc.$259
- AbbVie$233
- Biogen$214
- plus $2K from 20 others
What the payments were for
- Food & beverage$3,204100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $350 |
| Novartis | 19 | $349 |
| UCB, Inc. | 14 | $291 |
| SK Life Science, Inc. | 14 | $259 |
| AbbVie | 13 | $233 |
| Biogen | 13 | $214 |
| Teva Pharmaceuticals USA, Inc. | 14 | $197 |
| Amgen | 9 | $193 |
| Inari Medical, Inc. | 1 | $170 |
| Portola Pharmaceuticals, LLC | 1 | $117 |
| Amneal Pharmaceuticals LLC | 6 | $109 |
| Lundbeck LLC | 5 | $99 |
| AstraZeneca(2 entities) | 3 | $93 |
| Alnylam Pharmaceuticals Inc. | 4 | $84 |
| Genentech USA, Inc. | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Argenx US, Inc. | 3 | $63 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $44 |
| Harmony Biosciences LLC | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| MDD US Operations, LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Grifols USA, LLC | 1 | $18 |
| Bausch Health US, LLC | 1 | $18 |
| Aucta Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FlowTriever$170
- ClotTriever$170
- ANDEXXA$117
How this compares
$3,204 in reported general payments places this provider in the 65th percentile of 76 vascular neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dalfampridine ErDalfampridine | 11 | $11,587 |
| Gabapentin | 43 | $967 |
| Primidone | 29 | $947 |
| Carbamazepine | 11 | $741 |
| Levetiracetam | 17 | $410 |
| Memantine Hcl | 18 | $395 |
| Zonisamide | 13 | $362 |
| Atorvastatin Calcium | 21 | $264 |
| Rosuvastatin Calcium | 13 | $238 |
| Donepezil Hcl | 20 | $183 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Midland
- Ameer HassanHarlingen$1M
- John VolpiHouston$407K
- Lee BirnbaumSan Antonio$195K
- Amrou SarrajHouston$182K
- Sunil ShethHouston$54K
- Steven WarachAustin$32K
- Jefferson MileyAustin$28K
- Hamidreza SaberAustin$22K
- Haris KamalHouston$21K
- Sean SavitzHouston$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.